MH-associated diseases: who really needs a non-triggering technique?

Seminars in Anesthesia, Perioperative Medicine and Pain

Volumn 26, Issue 3, 2007, Pages 113-119

  Litman, Ronald S ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Anesthetic complications; Central core myopathy; Dystrophinopathy; Hyperthermia; Rhabdomyolysis; Ryanodine

Indexed keywords

ANESTHETIC AGENT; MUSCLE RELAXANT AGENT; SUXAMETHONIUM;

ADENOSINE MONOPHOSPHATE DEAMINASE DEFICIENCY; ARTHROGRYPOSIS; ARTICLE; CARNITINE PALMITOYL TRANSFERASE TYPE 2 DEFICIENCY; CENTRAL CORE DISEASE; CLINICAL FEATURE; CONGENITAL DISORDER; DEPOLARIZATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME DEFICIENCY; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; HYPERKALEMIA; HYPERMETABOLISM; KING DENBOROUGH SYNDROME; MALIGNANT HYPERTHERMIA; MITOCHONDRIAL MYOPATHY; MULTIMINICORE DISEASE; MUSCLE HYPOTONIA; MUSCLE RELAXATION; MUSCULAR DYSTROPHY; NEUROLEPTIC MALIGNANT SYNDROME; NOONAN SYNDROME; OSTEOGENESIS IMPERFECTA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECESSIVE INHERITANCE; RHABDOMYOLYSIS; SKELETAL MUSCLE;

EID: 34748926453     PISSN: 02770326     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sane.2007.06.007     Document Type: Article

References (54)

1. Denborough M.A., Forster J.F., Lovell R.R., et al. Anaesthetic deaths in a family. Br J Anaesth 34 (1962) 395-396
2. Ording H. Incidence of malignant hyperthermia in Denmark. Anesth Analg 64 (1985) 700-704
3. Bachand M., Vachon N., Boisvert M., et al. Clinical reassessment of malignant hyperthermia in Abitibi-Temiscamingue. Can J Anaesth 44 (1997) 696-701
4. Struk A., Lehmann-Horn F., and Melzer W. Voltage-dependent calcium release in human malignant hyperthermia muscle fibers. Biophys J 75 (1998) 2402-2410
5. Mickelson J.R., and Louis C.F. Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Physiol Rev 76 (1996) 537-592
6. Louis C.F., Zualkernan K., Roghair T., et al. The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology 77 (1992) 114-125
7. Rosenberg H., Antognini J.F., and Muldoon S. Testing for malignant hyperthermia. Anesthesiology 96 (2002) 232-237
8. Allen G.C., Larach M.G., and Kunselman A.R. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 88 (1998) 579-588
9. Litman R.S., and Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA 293 (2005) 2918-2924
10. Sei Y., Sambuughin N.N., Davis E.J., et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 101 (2004) 824-830
11. Wu S., Ibarra M.C., Malicdan M.C., et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 129 (2006) 1470-1480
12. Hughes M.I., Hicks E.M., Nevin N.C., et al. The prevalence of inherited neuromuscular disease in Northern Ireland. Neuromuscul Disord 6 (1996) 69-73
13. Gamble J.G., Rinsky L.A., and Lee J.H. Orthopaedic aspects of central core disease. J Bone Joint Surg Am 70 (1988) 1061-1066
14. Robinson R.L., Brooks C., Brown S.L., et al. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat 20 (2002) 88-97
15. McCarthy T.V., Quane K.A., and Lynch P.J. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 15 (2000) 410-417
16. Frank J.P., Harati Y., Butler I.J., et al. Central core disease and malignant hyperthermia syndrome. Ann Neurol 7 (1980) 11-17
17. Quane K.A., Healy J.M., Keating K.E., et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 5 (1993) 51-55
18. Zorzato F., Jungbluth H., Zhou H., et al. Functional effects of mutations identified in patients with multiminicore disease. IUBMB Life 59 (2007) 14-20
19. Guis S., Figarella-Branger D., Monnier N., et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 61 (2004) 106-113
20. King J.O., Denborough M.A., and Zapf P.W. Inheritance of malignant hyperpyrexia. Lancet 1 (1972) 365-370
21. Heiman-Patterson T.D., Rosenberg H.R., Binning C.P., et al. King-Denborough syndrome: contracture testing and literature review. Pediatr Neurol 2 (1986) 175-177
22. Hoffman E.P., Brown Jr. R.H., and Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51 (1987) 919-928
23. Brownell A.K., Paasuke R.T., Elash A., et al. Malignant hyperthermia in Duchenne muscular dystrophy. Anesthesiology 58 (1983) 180-182
24. Obata R., Yasumi Y., Suzuki A., et al. Rhabdomyolysis in association with Duchenne's muscular dystrophy. Can J Anaesth 46 (1999) 564-566
25. Rubiano R., Chang J.L., Carroll J., et al. Acute rhabdomyolysis following halothane anesthesia without succinylcholine. Anesthesiology 67 (1987) 856-857
26. Chalkiadis G.A., and Branch K.G. Cardiac arrest after isoflurane anaesthesia in a patient with Duchenne's muscular dystrophy. Anaesthesia 45 (1990) 22-25
27. Sethna N.F., and Rockoff M.A. Cardiac arrest following inhalation induction of anaesthesia in a child with Duchenne's muscular dystrophy. Can Anaesth Soc J 33 (1986) 799-802
28. Nathan A., Ganesh A., Godinez R., et al. Hyperkalemic cardiac arrest following cardiopulmonary bypass in a child with unsuspected Duchenne muscular dystrophy. Anesth Analg 100 (2005) 672-674
29. Girshin M., Mukherjee J., Clowney R., et al. The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne's muscular dystrophy. Pediatr Anesth 16 (2006) 170-173
30. Seay A.R., Ziter F.A., and Thompson J.A. Cardiac arrest during induction of anesthesia in Duchenne muscular dystrophy. J Pediatr 93 (1978) 88-90
31. Linter S.P., Thomas P.R., Withington P.S., et al. Suxamethonium associated hypertonicity and cardiac arrest in unsuspected pseudohypertrophic muscular dystrophy. Br J Anaesth 54 (1982) 1331-1332
32. Oka S., Igarashi Y., Takagi A., et al. Malignant hyperpyrexia and Duchenne muscular dystrophy: a case report. Can Anaesth Soc J 29 (1982) 627-629
33. Gronert G.A., Fowler W., et al. Absence of malignant hyperthermia contractures in Becker-Duchenne dystrophy at age 2. GH III. Muscle Nerve 15 (1992) 52-56
34. Yemen T.A., and McClain C. Muscular dystrophy, anesthesia and the safety of inhalational agents revisited, again. Pediatr Anesth 16 (2006) 105-108
35. Wu C.C., Tseng C.S., Shen C.H., et al. Succinylcholine-induced cardiac arrest in unsuspected Becker muscular dystrophy: a case report. Acta Anaesthesiol Sin 36 (1998) 165-168
36. Isaacs H., Badenhorst M.E., and Du S.C. Myophosphorylase B deficiency and malignant hyperthermia. Muscle Nerve 12 (1989) 203-205
37. Lobato E.B., Janelle G.M., Urdaneta F., et al. Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease. Anesthesiology 91 (1999) 303-305
38. Bollig G., Mohr S., and Raeder J. McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand 49 (2005) 1077-1083
39. Fricker R.M., Raffelsberger T., Rauch-Shorny S., et al. Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. Anesthesiology 97 (2002) 1635-1637
40. Katsuya H., Misumi M., Ohtani Y., et al. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiology 68 (1988) 945-948
41. Schaer H., Steinmann B., Jerusalem S., et al. Rhabdomyolysis induced by anaesthesia with intraoperative cardiac arrest. Br J Anaesth 49 (1977) 495-499
42. Tobin J.R., Jason D.R., Challa V.R., et al. Malignant hyperthermia and apparent heat stroke. JAMA 286 (2001) 168-169
43. Kochling A., Wappler F., Winkler G., et al. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intens Care 26 (1998) 315-318
44. Wappler F., Fiege M., Steinfath M., et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 94 (2001) 95-100
45. Martin S., and Tobias J.D. Perioperative care of the child with arthrogryposis. Pediatr Anesth 16 (2006) 31-37
46. Baines D.B., Douglas I.D., and Overton J.H. Anaesthesia for patients with arthrogryposis multiplex congenita: what is the risk of malignant hyperthermia?. Anaesth Intens Care 14 (1986) 370-372
47. Hopkins P.M., Ellis F.R., and Halsall P.J. Hypermetabolism in arthrogryposis multiplex congenita. Anaesthesia 46 (1991) 374-375
48. Rampton A.J., Kelly D.A., Shanahan E.C., et al. Occurrence of malignant hyperpyrexia in a patient with osteogenesis imperfecta. Br J Anaesth 56 (1984) 1443-1446
49. Porsborg P., Astrup G., Bendixen D., et al. Osteogenesis imperfecta and malignant hyperthermia. Anaesthesia 51 (1996) 863-865
50. Ryan C.A., Al-Ghamdi A.S., Gayle M., et al. Osteogenesis imperfecta and hyperthermia. Anesth Analg 68 (1989) 811-814
51. Kill C., Leonhardt A., and Wulf H. Lacticacidosis after short-term infusion of propofol for anaesthesia in a child with osteogenesis imperfecta. Pediatr Anesth 13 (2003) 823-826
52. Smego Jr. R.A., and Durack D.T. Neuroleptic malignant syndrome. Arch Int Med 142 (1982) 1183-1185
53. Caroff S.N., Rosenberg H., Fletcher J.E., et al. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 67 (1987) 20-25
54. Weglinski M.R., Wedel D.J., and Engel A.G. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 84 (1997) 1038-1041